{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:00:13Z","timestamp":1791648013128,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Reference Network on Hepatological Diseases"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jhep.2020.07.023","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T03:24:16Z","timestamp":1595301856000},"page":"1496-1506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-3129","authenticated-orcid":false,"given":"Ansgar W.","family":"Lohse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-6979","authenticated-orcid":false,"given":"Marcial","family":"Sebode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne H.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-5232","authenticated-orcid":false,"given":"Henriette","family":"Ytting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-8856","authenticated-orcid":false,"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Vesterhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.07.023_bib1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib3","first-page":"159","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.jhep.2020.07.023_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.07.023_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.07.023_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.07.023_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib9","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/hep.23840","article-title":"Treatment response in patients with autoimmune hepatitis","volume":"52","author":"Schramm","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib10","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2018.12.035","article-title":"Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis","volume":"17","author":"Pape","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"Van Gerven","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2036.2006.03113.x","article-title":"Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis","volume":"24","author":"Miyake","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy","volume":"99","author":"Verma","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse","volume":"102","author":"Montano-Loza","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(81)90126-8","article-title":"Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features","volume":"80","author":"Czaja","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.07.023_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/0891693021000056721","article-title":"Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease","volume":"35","author":"Gregorio","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2020.07.023_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","article-title":"Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis","volume":"68","author":"Hartl","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A\u00a0single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib23","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","article-title":"Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up","volume":"51","author":"Aw","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10620-018-5011-x","article-title":"Tacrolimus and mycophenolate mofetil as second-line therapies for\u00a0pediatric patients with autoimmune hepatitis","volume":"63","author":"Efe","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.07.023_bib27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.07.023_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gr\u00f8nb\u00e6k","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib29","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.07.023_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cgh.2019.11.013","article-title":"Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months","volume":"18","author":"Pape","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jhep.2009.10.004","article-title":"Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis","volume":"52","author":"Hindorf","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib33","first-page":"391","article-title":"Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report","volume":"35","author":"Rumbo","year":"2002","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00007890-199410150-00010","article-title":"Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes","volume":"58","author":"Bergan","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2020.07.023_bib35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.07.023_bib36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.49.5.665","article-title":"Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.07.023_bib37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","article-title":"Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine","volume":"5","author":"Sparrow","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.12223","article-title":"Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis","volume":"37","author":"de Boer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1542\/peds.41.1.52","article-title":"Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor","volume":"41","author":"Krakoff","year":"1968","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2020.07.023_bib42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2011.04848.x","article-title":"Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine","volume":"34","author":"Armstrong","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib43","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/MIB.0000000000000302","article-title":"Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC","volume":"21","author":"Bouguen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2020.07.023_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bpg.2018.06.003","article-title":"Variant syndromes of primary biliary cholangitis","volume":"34-35","author":"Schulz","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib45","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/00365521.2017.1311936","article-title":"Clinical and histologic features of azathioprine-induced hepatotoxicity","volume":"52","author":"Siramolpiwat","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MCG.0000000000000568","article-title":"Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes","volume":"51","author":"Bj\u00f6rnsson","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2016.05.023","article-title":"Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis","volume":"65","author":"Hartl","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1990.tb03606.x","article-title":"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6- thioguanine nucleotides in renal transplant patients","volume":"30","author":"Chan","year":"1990","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jhep.2020.07.023_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"H\u00fcbener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/apt.14939","article-title":"Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in The Netherlands","volume":"48","author":"van den Brand","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib51","first-page":"42","article-title":"Update on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J\u00a0Pediatr Genet"},{"key":"10.1016\/j.jhep.2020.07.023_bib53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.07.023_bib54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A\u00a0systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"De Lemos-Bonotto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","article-title":"Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine","volume":"51","author":"Giannakopoulos","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2020.07.023_bib56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib57","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jhep.2020.07.023_bib58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","article-title":"Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis","volume":"16","author":"Peiseler","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.07.023_bib59","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/hep.30031","article-title":"The impact of autoimmune hepatitis and its treatment on health utility","volume":"68","author":"Wong","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.07.023_bib60","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jim\u00e9nez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2020.07.023_bib61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000002776","article-title":"Autoimmune hepatitis in children: prednisone plus azathioprine vs cyclosporine: a randomized trial","volume":"71","author":"Cuarterolo","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib62","first-page":"18","article-title":"Evaluation of the\u00a0effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children","volume":"11","author":"Pniewska","year":"2016","journal-title":"Prz Gastroenterol"},{"key":"10.1016\/j.jhep.2020.07.023_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MPG.0000000000001563","article-title":"Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites","volume":"65","author":"Sheiko","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MPG.0000000000002146","article-title":"Lower 6-MMP\/6-TG ratio may be a therapeutic target in pediatric autoimmune hepatitis","volume":"67","author":"Bolia","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/MPG.0000000000001930","article-title":"Autoimmune hepatitis in children and adolescents: effect on quality of life","volume":"66","author":"Trevizoli","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib66","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0b013e3182602b20","article-title":"Autoimmune hepatitis in children in Eastern Denmark","volume":"55","author":"Vitfell-Pedersen","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2020.07.023_bib67","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1651-2227.2012.02745.x","article-title":"Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis","volume":"101","author":"Marlaka","year":"2012","journal-title":"Acta Paediatr"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820304700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820304700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:18Z","timestamp":1759174878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820304700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0168827820304700"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.07.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}